Epirubicin is a cancer medication that interferes with the growth and spread of cancer cells in the body. Epirubicin is an Anthracycline topoisomerase II inhibitor indicated as a component of adjuvant therapy in patients with evidence of Axillary node tumor involvement, following resection of primary breast cancer. Similarly to other Anthracyclines, Epirubicin acts by intercalating DNA strands. Intercalation results in complex formation which inhibits DNA and RNA synthesis. It also triggers DNA cleavage by Topoisomerase II, resulting in mechanisms that lead to cell death.

Potential Indication

EPIRUBICIN is approved by the FDA for treatment of:

  • Breast Cancer
  • Bone Marrow Dysfunction
  • 10 mg
  • 20 mg
  • 50 mg
  • 150 mg
  • 200 mg